Chairman’s Message
Shareholder Update

March 11, 2010

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path timeframes for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

The end of 2008 and going into early 2009 the company believed it would finalize product development by the end of 2009 with first deliveries during the first quarter of 2010. That has obviously proven to be an overly optimistic time frame, and I accept responsibility for not being more conservative with our projections at that time. Those projections were based on statements made to me by our development partner that the prototype equipment being planned for full-scale room treatment “would be very close to a production prototype.” This clearly has not proven to be the case.

As projects like this involving revolutionary technology and break through science evolve, they do have a tendency to take on a life of their own. Relative to the development of the room scale prototype, initially our development partner fell behind expectations relative to delivery time. Also, and this is a very big positive, on January 5, 2010 we announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.” Those first 6-log results were achieved in our laboratory unit with technology that had not yet been integrated into our full-scale equipment. This incredible scientific accomplishment was explained in the January 10, 2010 press release relating to greatly enhanced patent protection. “This was made possible”, commented Dr Michael Shannon, Medizone’s Director of Medical Affairs, “through the integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative.”

In sum, the goal posts had moved. Additional technologies that greatly enhanced the AsepticSure™ product now had to be integrated into a design that had not originally been considered for this additional technology that greatly enhanced efficacy. Thus, in reality, what was once intended to be “very close to a production prototype,” had clearly become a development machine that required additional engineering prior to being ready for hospital beta testing and production. During the last half of 2009, I tried to soften expectations relative to commercialization time frames in both how press releases were drafted and also with our SEC Filings. I hope this communication will clear up once and for all any misunderstanding.

Currently, utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what we expect the full production prototype will be. Shareholders must comprehend, now that we understand the science and clearly understand what is required for open space sterilization such as in hospital settings, it is absolutely essential to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use and the equipment must be 100% reliable. Anything short of that is a recipe for failure. Medizone Management from top to bottom and all of our development staff, are dedicated to that outcome; deliver a first rate, reliable machine, that hospitals can count on. Nothing less will do.

Since I want to be cautious with time frames given past slippages, hospital beta testing is expected to begin by late spring at sites in both the US and Canada. Production developments from the hospital beta system are not expected to be in the hardware or basic design, but more related to things like state of the art packaging. However, let me caution, as I stated earlier in this communication, these things do have a way of taking on a life of their own.

We believe moving from hospital beta testing to initial production and sales at modest rates should prove to be a smooth, manageable transition. We expect sales should flow smoothly out of a successful beta test program. In closing, I think it is important for shareholders to remember that Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. We expect the same success in commercialization.

We are still a small company with limited resources. I am proud of what we have achieved. It is absolutely essential that we not rush this next phase of product development, as it must be done correctly the first time. I assure you both Dr Shannon, myself and all of our team, are putting our full effort into making sure that is the case.

As we successfully transition into hospital beta testing, when the first peer reviewed journal article is published (expected this summer), as partners are announced and the management team and board are expanded to reflect the skill sets of a rapidly growing commercially viable company, our contribution to science and medicine will be clear to all.

Yours truly,

Edwin G. Marshall
Chairman &
CEO
Medizone International, Inc.

This Chairman’s message contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

(OTCBB:  NXTH)

Talk about Media Savvy — this company gets it.  Not ONLY with the celebrity endorsements but with an incredible internet campaign.

National Celebrities focused on fitness have endorsed NXTH.

Shaquille O’Neal, National Basketball Association star, Eddie George and Blair Underwood Public Face of Susta™ and NXT Nutritional Holdings, Inc.

Shaquille O’Neal will be a spokesman for NXT Nutritionals to educate children and adults about how SUSTA™ Natural Sweetener can help them curb the country’s growing epidemic of obesity and diabetes and increase market awareness of the SUSTA brand. O’Neal is a 15-time NBA All-Star, 4-time World Champion, 3 time NBA Finals MVP and is currently playing for the Cleveland Cavaliers.

O’Neal stated his goal is to educate children and adults that SUSTA is the first sweetener that helps maintain a healthy lifestyle because SUSTA not only tastes great, but also contains probiotics as well as important vitamins and minerals.

Shaquille O’Neal will support the Company’s national awareness campaign for SUSTA Natural Sweetener because it is the only sweetener that is all-natural, low glycemic, contains soluble fiber and probiotics, vitamins C, B6 and B12 and essential minerals and that helps to maintain healthy blood sugar levels, aids digestion as well as supports the immune system.

In 2007, Shaquille hosted a reality TV show on ABC, “Shaq’s Big Challenge,” which featured O’Neal’s effort to help six severely obese middle school aged children from Broward County, Florida to lose weight and gain a healthy lifestyle. The children all started out overweight and were unable to produce adequate results in the President’s Physical Fitness Test and by the end of the challenge they had all lost weight and passed the President’s Physical Fitness Test in all areas.

Eddie George, a Heisman Trophy winner, will promote SUSTA™ Natural Sweetener and Healthy Diary® Yogurt Smoothies in its nationwide expansion.

To raise awareness of the SUSTA brand when SUSTA arrives in Kroger stores in the Columbus, Ohio, area, Eddie George will be making in-store appearances, local television and radio interviews.

George has been an advocate for improving health and wellness among Americans. For the past three years, he and his wife Taj have teamed up with Dr. Oz on “The Dr. Oz Show.” Together they coached and motivated the moms throughout the 2009 NFL season as part of a national viewer challenge to inspire moms and families everywhere to improve their health. The winner of the challenge was announced on the website of the “The Dr. Oz Show.”

In 2006, George was named a spokesperson for Tennessee’s GetFitTN program by Governor Phil Bredesen. GetFitTN is a statewide awareness program to address the rising epidemic of Type 2 diabetes and risk factors that lead to diabetes, such as obesity. This initiative is aimed at educating both adults and children that Type 2 diabetes can be delayed or even prevented with modest lifestyle changes such as increasing physical activity and a healthier diet.

Blair Underwood, an American television and film actor, director, producer and entrepreneur Blair Underwood, will serve as the national spokesperson for NXT Nutritionals and its SUSTA™ Natural Sweetener. For over 20 years, Mr. Underwood has had a successful career playing a wide variety of roles on numerous television and feature films, including his breakout role as a brash attorney on the popular legal drama “L.A. Law” for seven years, his role on the HBO series “In Treatment,” his recurring role on the sit-com “The New Adventures of Old Christine” with Julia Louis-Dreyfus, and his role as Dr. Robert Leeds on the popular HBO series “Sex and the City.” Mr. Underwood has earned two Golden Globe nominations and six NAACP Image awards for offering audiences multi-faceted characters including lawyers, doctors and executives in his film and television work. In addition, Mr. Underwood earned a Grammy Award this year for “Best Spoken Word Album” narrating (with Cynthia Nixon and Beau Bridges) Al Gore’s audio book, “An Inconvenient Truth.” Underwood’s versatility, compelling screen presence, and take-charge appeal proved to be a consistent crowd pleaser with audiences and critics alike. Additionally, Mr. Underwood has produced and directed several short movies and music videos, and is also known for his major contributions through his philanthropic efforts.

Mr. Underwood will represent NXT Nutritionals and their SUSTA™ Natural Sweetener. Blair Underwood is focused on delivering the Company message which addresses the growing epidemic of obesity and diabetes in our country and profiling SUSTA™ Natural Sweetener as a natural healthy alternative to table sugar and the existing artificial sweeteners on the market. Maintaining healthy blood sugar levels, aiding in digestion, and supporting the immune system are critical to a healthy lifestyle. He will educate consumers about the benefits of using SUSTA™ Natural Sweetener.

IN ADDTION NXT Nutritional’s Has a Massive Marketing Campaign

NXT Nutritionals’ has and established broad campaign to increase awareness of the Company’s SUSTA™ Natural Sweetener.

USA Today The paper has the widest circulation of any newspaper in the United States, averaging over 2.11 million copies every weekday.

Go Dairy Free
Review: SUSTA Natural Sweetener (Vegan, Gluten-Free, Nut-Free, Soy-Free)

Broken TeePee
Review: All Natural Sweetener – SUSTA
February 2, 2010

Boston Herald
Company Shoots for Jump in Low-Cal Sweetener’s Sales
January 25, 2010

Healthy Product Reviews
SUSTA Natural Sweetener
January 22, 2010

Non-Dairy Queen
SUSTA Sweetener Review
January 11, 2010

Gluten Free Is Life
Product Review: SUSTA Natural Sweetener
January 8, 2010

The Dirty T-Shirt
Review and Give Away
January 10, 2010

NECN.com Business
BBJ: SUSTA Gains Star Power of Shaq, Underwood
December 30, 2009

Functional Ingredients
New Product: New Fructose-Based Sweetener Stands Up To Stevia
November 11, 2009

Supermarket Guru
Phil Lempert Review
November 4, 2009

Mommys A Waitress
SUSTA Natural Sweetener Review
November 4, 2009

Health & Beauty Close-Up
NXT Nutritional Touts ‘SUSTA’ All-Natural Sweetener
September 16, 2009

That’s Fit
SUSTA is Sweet on Your Tummy and Gut
September 14, 2009

Slashfood
New Sweetener SUSTA Hits Stores
September 10, 2009

Strong Website Presence

Excellent Website Videos Explain Company Dynamics: http://vimeo.com/5591507

The company has dynamic and attractive commercials as well which can be viewed from their website.

NXT Nutritional’s Website offers extensive corporate and retail information providing easy access and credibility to the company.

NXT Nutritionals Holdings, Inc.
President and CEO: Michael McCarthy
800-535-4315
NXT Nutritionals’ corporate website: http://www.nxtnutritionals.com/
Contact: moreinfo@nxtnutritionals.com

Public Relations/Media: Stern & Co.
Richard Stern
212-888-0044
Contact: richstern@sternco.com

Forward-Looking Statements : Under The Private Securities Litigation Reform Act of 1995: The statements in this profilethat relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. No obligation is assumed to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of NXT Nutritionals Holdings, Inc. can be found in the filings of NXT Nutritionals Holdings, Inc. with the U.S. Securities and Exchange Commission.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was paid seven thousand five hundred dollars by a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of NXT Nutritional Holdings, Inc. (OTCBB: NXTH) during the promotional period.

Vicor Technologies, Inc. (OTCBB: VCRT)

Vicor Technologies, Inc. is quickly becoming a biotechnology which is commercially viable.  And while I really do not expect you to read each and every Field Trial Entry, Application and Scientific Presentation listed below  – I would like you to take a look at the quality and quantity of trials and presentations.

This vast group of Field Trials, Presentations and Publications represents a text book example of a Bio-Technology Company that has delivered a scientifically significant product recognized in the medical community.

These Field Trials, Presentations and Publications lay the ground work for an incredible shareholder opportunity.  And this comes on top of the recent association with the leading medical university in Equador with the Universidad San Francisco de Quito in Ecuador.  This one collaboration has the potential to vastly enhance shareholder value — and serves as a blueprint for future itnernational commercial awareness.

Current Field Trials and Applications

Vicor has determined the most appropriate rollout of their product is in controlled environments which produce crucial feedback for product enhancement.  This means they have the credibility of the Field Trials, Presentations and Publications but they are actively seeking feedback for users in the field.  The medical professionals that make the financial purchase decisions.  This is smart, smart, smart.

PD2i™ Application in London

PD2i™ nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a cardiac screening initiative to be held in London and Southeast England, commencing in April 2010. Dr. Sharma, consultant cardiologist of Cardiac Risk in the Young (CRY), is spearheading the screening initiative which will offer free cardiac screening to 14 year olds (DOB 1995) living in London and Southeast England; fourteen is the earliest post-puberty age for which proactive screening is considered viable. Ten percent of the estimated seven million individuals fitting this description are expected to participate.

The ultimate goal of this initiative is to develop a prototype for a national screening program for young sudden cardiac death, which is an extremely worthy goal, given that some 600 young people are struck down by sudden cardiac death annually in the U.K.

Application Service Provider Distribution Model

A major U.S. cardiology practice serves as the Company’s beta test site for Vicor’s Application Service Provider distribution model which enables the seamless collection and transmission of patient EKG data to the Vicor server for analysis.

Vicor’s software residing on the Company’s servers will complete the analysis of the EKG data read by the PD2i Analyzer™. The physician then receives an electronic medical record and report of the PD2i Analyzer™ results.

The Application Server Provider distribution model records physician use to Vicor’s website to enable automated monthly billing of physicians using its PD2i Analyzer™ and reimbursable under existing CPT codes.

Normal Range Study for the PD2i Analyzer™ Will Serve As Basis For Test Interpretation.

Vicor will be performing a normal range study for the PD2i Analyzer™ at the University of Mississippi Medical Center as soon as routine Institutional Review Board approval is received. This study of approximately 400 age and gender matched “normal” patients will enable us to identify and establish normal ranges of PD2i™ values for these groups, for both a resting patient and a patient performing paced respiration and/or controlled exercise. Vicor will then file a 510(k) with the FDA to establish normal ranges for PD2i™ values. The ability to identify normal ranges will help physicians interpret the results of a PD2i Analyzer™ test as abnormal or normal, which will facilitate accurate diagnosis and appropriate treatment.

Collaborative Studies Continue to Show the PD2i™ Nonlinear Algorithm Enables Accurate Triage of the Seriously Wounded

Testing of the PD2i VS™ by the U.S. Army is continuing under the Company’s collaborative agreement. In the completed study of 325 civilian trauma patients, researchers found that analysis of complex heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using both “raw” or “clean” electrocardiograms (“EKG’s”). This latter point is especially important considering the real world – on the battlefield or in civilian trauma settings – in which EKG data is collected. This data for the PD2i VS™ will be used to file a 510(k) to establish a claim for a more accurate triaging of trauma patients.

Additionally, Vicor has completed the programming necessary for the PD2i VS™ to operate as a continuous vital sign monitor. In this mode, the PD2i VS™ provides an initial PD2i™ result within three minutes of collected data and then an updated status every minute thereafter. Each result is accompanied by an audible tone, and a green, yellow, or red light to indicate the patient’s change in status and alert the emergency response team of a need for aggressive and immediate lifesaving intervention. Vicor is completing the modification of the R-R detector in the Company’s software to improve its already high sensitivity and accuracy. (The accuracy of the time intervals between each heart beat “the R-R interval” is critical to the calculation of a PD2i™ value.)

The enhanced version of the continuous PD2i VS™, together with the improved RR detector should enable the USAISR to utilize the Company’s technology in an important prospective human trial.

The PD2i CA™ (Cardiac Analyzer) Expected to Utilize MUSIC Trial Data for New 510(k)

Under a collaborative agreement with the University of Rochester and the Catala Institute of Cardiovascular Science, the PD2i CA™ is being used to study the data files of 651 individuals who participated in the Merte Subita en Insufficiencia Cardiaca (MUSIC) congestive heart failure trial. Vicor has completed analysis of the data files, and expects to have the Company’s collaborators unlock the clinical data and compare the PD2i CA™ results with the actual clinical outcomes in the next six to eight weeks. This time period will permit Vicor to modify the R-R detection software in order to re-analyze the files. This second analysis will enable Vicor to maximize the already high probability of success of this important trial data set. This data set is then expected to serve as the basis for submission of a 510(k) to the FDA for the application of sudden cardiac death (SCD).

Publications, Presentations and Papers

During the past year, the results of the Company’s efforts have appeared in trade media reaching important target audiences, prestigious medical journals, and presentations by USAISR medical personnel.

Trade Media

Dr. Daniel N. Weiss, the Company’s Chief Medical Officer, was interviewed by EP Lab Digest. Medical Device Daily included Dr. Weiss’s comments in an article entitled “Vicor’s heart metric used as an identifier for trauma in patients” (September 25, 2009).

Colonel Leopoldo Cancio of the USAISR identified the PD2i™ as a heart-rate complexity metric to be tested on trauma patients in the Army’s new Critical Combat Care Engineering (C3E) program in “Bridging the Critical Care Chasm,” an article describing the C3E that appeared in the August 2009 issue of Military Medical/CBRN
Technology (Volume 13, Issue 5).

The C3E is a new program area within the U.S. Army Medical Research and Materiel Command’s Combat Casualty Care Research Area Directorate (RAD II) that was created to improve battlefield care and, specifically, address the “critical care technology gap.”

Peer-Reviewed Medical Journals

A manuscript of Vicor’s study, “Comparison of linear-stochastic and nonlinear deterministic algorithms in the analysis of 15-minute clinical EKGs to predict risk of arrhythmic death,” appeared in Therapeutics and Clinical Risk Management (2009-5, 1-12).

The manuscript chronicles the study of 397 patients admitted to three emergency room departments for chest pain and determined to be at low-to-high risk of acute myocardial infarction (MI). Fifteen-minute EKGs were recorded and R-R intervals assessed by three non-linear algorithms (PD2i™, DFA, and ApEn) and four conventional linear-stochastic measures (SDNN, MNN, 1/f-Slope, LF/HF). The sensitivity and relative risk for predicting arrhythmic death was highest at all time-points for the PD2i™ algorithm.

“New Measures of Heart-Rate Complexity: Effect of Chest Trauma and Hemorrhage” is in press in the Journal of Trauma. This USAISR study analyzed the complex beat-to-beat variability present in the heart-rate time series, which has been proposed as a “new vital sign.”

The effect of chest trauma and hemorrhagic shock on heart-rate complexity (HRC) was examined in an animal model. The study concluded that heart rate complexity may be useful for diagnosis of trauma and hemorrhagic shock, and for monitoring resuscitation efforts.

University of Rochester/Catalan Institute of Cardiovascular Sciences

Vicor is working with the University of Rochester and the Catalan Institute of Cardiovascular Sciences to use the PD2i CA™ to retrospectively predict sudden cardiac death in the 651 congestive heart failure patients studied by the Muerte Subita en Insuficiencia Cardiaca (MUSIC) trial, in which 52 actually died from SCD.
Vicor expects that the results of this analysis will be sufficient to support FDA 510(k) clearance for sudden cardiac death in 2010.

University of Mississippi Medical Center

Vicor is collaborating with the University of Mississippi Medical Center on several trials:

Brain Injury Risk Stratification Trial

The BIRST trial will determine the ability of the PD2i™ nonlinear algorithm to predict mortality in victims of brain trauma. PD2i™ will also be assessed for its ability to track the clinical status of neuro-trauma ICU patients.

Brain trauma is a serious public health challenge. In the U.S. over 300,000 sport-related traumatic brain injuries occur annually, and according to the Brain Trauma Foundation, approximately 52,000 will die.

Cardiac Arrhythmia Assessment and Safety in Athletes (CAASA)

Sudden cardiac death is a leading cause of death among student athletes. The CAASA trial will test the ability of the PD2i CA™ to identify those at risk.

The CAASA trial will commence at the University of Mississippi, with follow-on studies at other prestigious universities.

Complexity Analysis Studies of Trauma in the Emergency Department (CASTED)

Vicor is in discussions with the University of Mississippi Medical Center Trauma Center to identify a means of transmitting PD2i-VS™ data during Medivac transport of civilian trauma victims.

Complexity Analysis during Blood Donation (CABLD)

In cooperation with the University of Mississippi Medical Center Blood Bank, the CABLD trial is testing the ability of the PD2i-VS™ to detect mild-to-moderate blood loss as determined during blood donations.

Complexity Analysis during Renal Dialysis (CARD) Trial

CARD will test the use of Heart Rate Variability to evaluate the effect of fluid loss during dialysis.

Massachusetts General Hospital MGH PD2i-VS Trial

In this study, Massachusetts General Hospital will test the PD2i-VS™ for real-time mobile & ICU triage in an extremely demanding emergency medical environment.

The teaching hospital for Harvard Medical School, MGH is a Level 1 Adult, Pediatric and Burn Trauma Center admitting over 4,000 trauma and emergency surgery patients annually.

Dr. Alfred Buxton and Heart Rate Variability

Vicor will be working with renowned electrophysiologist, Dr. Alfred Buxton, on two trials to learn if measuring Heart Rate Variability is useful in tracking the progress of cardiac patients undergoing various rehabilitative treatments following ICD implantation.

Dr. Buxton is a Professor of Medicine at Brown Medical School and Director of the Cardiology Division at Brown Medical School, and Rhode Island and Miriam hospitals. He is also the Director of Arrhythmia Services and the Clinical Cardiac Electrophysiology Laboratory at Rhode Island and Miriam hospitals.

CARE-t Trial

Vicor’s PD2i Analyzer™ will be used to measure Heart Rate Variability as a means of determining the efficacy of cognitive behavioral therapy on cardiac patients with ICDs.

CARE-e Trial

Vicor’s PD2i CA™ is being used to determine the ability of exercise to reduce arrhythmias in cardiac patients with ICDs.

Target Health, Inc.

Target Health, Inc. is working as the Company’s Contract Research Organization in regulatory matters as strategic advisors and clinical consultants for meetings with the FDA.

The Sudden Cardiac Arrest Association

Vicor supports the work of the Sudden Cardiac Arrest Association. The SCAA identifies and unites survivors, those at risk of sudden cardiac arrest, and those interested in advocating for SCAA issues in their communities and beyond. The Sudden Cardiac Arrest Association and Vicor share a mission: to prevent loss of life from Sudden Cardiac Arrest.

PD2i VS™ Presentations and Publications 2009 ATACCC Conference / Smart Monitoring 2009 Forum

Vicor’s technology was presented in August at the 2009 Advanced Technology Applications for Combat Casualty Care (ATACCC) conference and the 2009 Smart Monitoring Forum in St. Petersburg Beach, Florida.

Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), made two presentations. The first, Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram, was presented at Smart Monitoring 2009 during the New Vital Signs, Predictive Variables and Indices panel.

At ATACCC, Dr. Batchinsky presented Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage? Both presentations reviewed findings from trials the USAISR has done with Vicor and described use of the PD2i-VS™ as a new vital sign in trauma triage.

The premier scientific meeting of the Department of Defense, ATACCC addresses advances in trauma medicine and the unique medical needs of the war fighter, identifying technologies that can meet increasingly complex operational issues.

Sponsored by the Resuscitation Research Laboratory of the University of Texas Medical Branch, Smart Monitoring is a forum on vital sign monitoring for combat casualty care, facilitating communication between industry representatives and medical experts from government, academia, and the private sector.

2008 International Shock Congress

Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was also presented by the U.S. Army in June, 2008 at the International Shock Congress in Cologne, Germany. The abstract concerned the initial experiment for trial performed by the U.S.Army on battlefield wounded soldiers utilizing Vicor’s PD2i™ technology.

PD2i ™Technology. Journal of Critical Care

Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was published in the June, 2008 Journal of Critical Care.

The Company’s first collaborative effort with the U.S. Army, this study involved combat casualties for whom EKG files were analyzed by several competing methods. Vicor’s PD2i™ technology correctly identified the need for immediate life-saving intervention.

Reference: Exploration of heart-rate complexity to determine the need for lifesaving interventions in combat casualties. Journal of Critical Care 2008 Jun;(Vol. 23, Issue 2, Pages 265-266)

Presentations

Andriy Batchinsky, MD, a USAISR researcher, presented findings from a study of Vicor’s PD2i VS™ at the American Heart Association’s Resuscitation Science Symposium 2009 (November 14-15, 2009). Dr. Batchinsky presented “Does Heart-Rate Complexity Analysis Work in the Real World? Changes in the Point Correlation Dimension of Heart Rate during Prehospital Lifesaving Interventions.”

This was the first presentation at a major scientific conference featuring Vicor’s proprietary PD2i™ nonlinear algorithm. The objective of “Does Heart-Rate Complexity Analysis Work in the Real World?” was to evaluate the ability of the PD2i VS™ to distinguish trauma patients receiving lifesaving interventions from those who did not based on analysis of EKGs from 325 pre-hospital trauma patients. The PD2i™ nonlinear algorithm value was calculated on both unedited (raw) and on manually verified, noise-and ectopy-free (clean) EKG sections. In conclusion, researchers found that analysis of heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using either “raw” or “clean” EKGs. Additional studies of automated trauma triage using the PD2i VS™ are planned

Additionally, Dr. Batchinsky made the following presentations of the USAISR’s continuing studies of the PD2i VS™:

“Are We Listening to Music or Noise? Use of the Lyapunov Exponent for Comprehensive Assessment of Heart Rate Complexity during Hemorrhage in Sedated Conscious Miniature Swine” 8th International Conference on Complexity in Acute Illness – August 28-30, 2009 – Palo Alto, CA

“Complexity in Animal Models” and “Continuous Complexity Analysis and Remote Battlefield Triage” International Experts of Complexity and Variability at the Bedside Round Table – August 24-25, 2009 – Wakefield, CA

“Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage?” ATACCC 2009 Conference – August 10-12, 2009 – St. Petersburg Beach, FL

“Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram” Smart Monitoring 2009 Conference – August 9, 2009 – St. Petersburg Beach, FL

Papers

Therapeutics & Clinical Risk Management

Vicor’s study, Nonlinear Analysis of the Heartbeats in Public Patient EKGs Using An Automated PD2i™ Algorithm for Risk Stratification of Arrhythmic Death was published in the April 2006 Therapeutics and Clinical Risk Management. This study demonstrated the ability of the PD2i CA™ to risk-stratify patients’ risk for sudden cardiac death and identify those who require ICD’s (implantable cardioverter defibrillator) and those who do not.

The study enrolled 37 patients and showed the PD2i test to have a sensitivity of 100% and a specificity of 85%. In other words, Vicor’s PD2i™ nonlinear algorithm correctly identified every patient who went on to suffer a cardiac arrest or sudden cardiac death, while only recommending over-treatment of 15%. Current risk-stratification criteria results in over-treatment of 76% of cases,1,2 while only identifying a fraction of “true-positives” — patients who will go on to experience cardiac arrests or sudden cardiac death.

Risk Stratification for Arrhythmic Death in an Emergency Department Cohort: A New Method of Non-Linear PD2i Analysis of the EKG

The Company’s study of 918 patients in six emergency departments, appeared in the August 2008 issue of Therapeutics and Clinical Risk Management. Vicor’s PD2i® algorithm and software achieved a sensitivity of 96% and a specificity of 85% with a negative predictive value of 99%.

Comparison of Linear–Stochastic and Nonlinear Deterministic Algorithms in the Analysis of 15-Minute Clinical EKGs to Predict Risk of Arrhythmic Death

Published August 17th in Therapeutics & Clinical Risk Management.
The paper describes a study in which 397 emergency room patients presenting with chest pain were evaluated by seven methodologies: the PD2i™ nonlinear algorithm, DFA, ApEn, SDNN, MNN, 1/f-Slope, and LF/HF. The study demonstrated that the PD2i™ nonlinear algorithm, based on a deterministic model, provided superior assessment of Heart Rate Variability in brief EKGs compared to measures based on either the linear stochastic model or other nonlinear ones, and thus provides the basis for a rapid, accurate, and cost-effective stratification of risk of AD among patients presenting in an Emergency Department.

Journal of Critical Care
Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was published in the June 2008 Journal of Critical Care. The Company’s first collaborative effort with the U.S. Army, this study involved combat casualties for whom EKG files were analyzed by several competing methods. Vicor’s PD2i™ nonlinear algorithm was the only method that correctly identified the need for immediate life-saving intervention in all cases.

American Heart Journal
A Reduction in the Correlation Dimension of Heartbeat Intervals Precedes Imminent Ventricular Fibrillation in Human Subjects appeared in Elsevier’s American Heart Journal. In this study, the PD2i™ nonlinear algorithm and software demonstrated a sensitivity of 100% and a specificity of 83%.

Ongoing Studies
In addition, Vicor is currently involved in several ongoing studies which will be submitted to appropriate publications when complete.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

Muscle Flex, Inc. (OTC: MFLI)

VIEW THE PROFILE

Muscle Flex, Inc. (OTC: MFLI)

VIEW THE PROFILE

.

.

Disclosure: Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure for MFLI: Pentony Enterprises LLC expects to be compensated a total of 750,000 shares from a non-affiliated third party for three sends to our database as an advertisement for MFLI. We have also been compensated $10,000 from the company and anticipate being paid another $5000 in February 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We currently hold no shares.

]]> http://www.stockguru.com/2010/03/breaking-news-muscle-flex-inc-otc-mflibravada-muscle-flex%c2%ae-to-create-television-and-media-division/feed/ 0 http://www.stockguru.com/2010/03/coroware-inc-is-in-the-stockguru-spotlight-for-march-11-2010/#utm_source=feed&utm_medium=feed&utm_campaign=feed http://www.stockguru.com/2010/03/coroware-inc-is-in-the-stockguru-spotlight-for-march-11-2010/#comments Thu, 11 Mar 2010 06:28:11 +0000 Editor http://www.stockguru.com/?p=9382  

DALLAS, TEXAS : StockGuru announces that CoroWare Inc. (OTCBB: COWI) is in the StockGuru Spotlight.   CoroWare is a solutions integrator with expertise in mobile robotics and personal telepresence. 

On Wednesday, the company put out news announcing that the company has added a new accessory to its growing line of robotics products.  A compact and affordable laser range finder is the latest addition to the company’s online product catalog. The laser range finder can be purchased individually or as an option on the CoroBot and Explorer robots. Purchased as a robot option, the laser comes fully installed with drivers pre-loaded on the robot’s computer. A 10Hz scanning frequency and range of over 18 ft. significantly increases the robots’ sensing power.

Shares for CoroWare Inc. (OTCBB: COWI) were down during the day of trading on Wednesday and closed slightly down at closing.

To view our StockGuru Spotlight on CoroWare Inc. (OTCBB: COWI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

DALLAS, TEXAS : StockGuru announces that Minatura Gold (OTCBB: MGOL) is in the StockGuru Spotlight.   Minatura Gold is a US-based public company in the business of exploration, development and, ultimately, extraction of precious metals in Colombia, South America. Minatura is dedicated to enhancing shareholder value while adhering to the highest environmental standards in its projects and creating legacy micro-economies for the communities in which Minatura operates. 

On Wednesday, the company put out news announcing that the company completed the drilling of the first of a 50-hole drilling program in certain gold mining concessions located in Colombia’s Department of Antioquia on 1,775 acres, including the Coco Hondo and Angostura properties (the “Zaragoza Project”). MGOL believes that these areas combine to contain an estimated 50 million cubic meters of material.

Shares for Minatura Gold (OTCBB: MGOL) were up during the afternoon of trading on Wednesday and closed up one dollar at closing.

To view our StockGuru Spotlight on Minatura Gold (OTCBB: MGOL), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

On Wednesday, the company put out news announcing that the company is significantly reducing its fees to cardholders for ATM withdrawals and also for electronic bill pay transactions. The Company believes that these reductions will encourage greater trial and usage of its Visa® and Discover® Reloadable Prepaid Cards and promote greater retention among cardholders.

Shares for nFinanSe Inc. (OTCBB: NFSE) were steady during the day of trading on Wednesday and closed with no change at closing.

To view our StockGuru Spotlight on nFinanSe Inc. (OTCBB: NFSE), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

On Wednesday, the company put out news announcing the beginning of the development of their Barnett Shale assets. Exterra will be partnering with Newtech Engineering to drill their 6 proven drilling locations in the Barnett Shale.  Exterra plans to drill these Horizontal wells over the next 9-12 months and expects first 12 months net revenue after operations to be over $9,000,000.  The assets that Exterra plans to drill are located in the tier 1 and 2 areas. These areas have shown to typically come on line at 1-1.5 MMCFD and will be producing an estimated 8 MMCFD after all of the wells are online. Exterra believes that we can have all of these wells drilled and online within the next 6-9 months.

Shares for Exterra Energy Inc. (OTCBB:EENI) were down during the late afternoon of trading on Wednesday and closed down four cents at closing.
 

To view our StockGuru Spotlight on Exterra Energy Inc. (OTCBB:EENI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

On Wednesday, the company put out news announcing a further update regarding the status of its agreement with Merck Chimie s.a.s. (”Merck Chimie”).  As mentioned in the Company’s prior announcement and Current Report on Form 8-K filed on November 24, 2009, Merck Chimie completed their encapsulation of a “test batch” of CardioGenics’ proprietary paramagnetic beads (the “CardioGenics Beads”) and targeted December 2009 for delivery of the CardioGenics Beads to the Company for “bench testing” to determine adherence of the encapsulated beads to specifications established jointly by Merck Chimie and CardioGenics for the commercial product. In December 2009, the Company received the encapsulated “test batch” of the CardioGenics Beads from Merck Chimie and performed the necessary bench testing.

Shares for CardioGenics Holdings Inc. (OTCBB: CGNH) were down during the late afternoon of trading on Wednesday and closed slightly down at closing.
 

To view our StockGuru Spotlight on CardioGenics Holdings Inc. (OTCBB: CGNH), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

On Wednesday, the company put out news announcing that the company’s largest secured creditors, Global Project Finance and Renn Capital, extended the maturity date of $44.65 million of debt to December 31, 2014. PetroHunter paid accrued interest to these creditors with restricted shares of its common stock, valued at $0.125 per share. Going forward, interest will be accrued but paid at maturity, together with the debt principal.

Shares for PetroHunter Energy Corp. (OTCBB: PHUN) were up during the late afternoon of trading on Wednesday and closed slightly up at closing.

To view our StockGuru Spotlight on PetroHunter Energy Corp. (OTCBB: PHUN), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (”SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com